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Background: Paradoxical inflammations during anti-TNF-α therapy are defined as adverse effects such as psoriasiform
skin lesions, uveitis and sarcoidosis-like granulomas induced by immune reactions, not by infectious agents. Here, we
report a very rare case of the simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with
refractory Crohn’s disease during infliximab therapy and both of which resolved spontaneously without the cessation
of infliximab.
Case presentation: In September 2000, 23-year old Japanese male was diagnosed with Crohn’s disease. Prednisolone
in combination with mesalazine was introduced at first and succeeded for almost one year. In June 2002, since his
gastrointestinal symptoms relapsed and were refractory, infliximab (IFX) therapy 5 mg/kg was introduced. In February
2011, because he had repeated arthralgia almost every intravenous IFX administration, IFX was increased to 10 mg/kg
under the diagnosis of a secondary failure of IFX. In December 2012, he complained of slight dry cough and an
itchy eruption on both lower limbs, and he was referred to our hospital due to the appearance of bilateral hilar
lymphadenopathy on chest X-ray examination. Chest computed tomogram revealed bilateral hilar lymphadenopathy
and fine reticulonodular shadows on the bilateral upper lungs. Serum calcium, angiotensin-converting enzyme and
soluble interleukin 2 receptor levels were not elevated, but the titer of antinuclear antibody was considerably elevated.
Mycobacterium infection was carefully excluded. Trans-bronchial lung biopsy showed non-caseating epithelioid cell
granulomas compatible with sarcoidosis. The skin biopsy of the right limb was diagnosed as leukocytoclastic vasculitis.
The patient was diagnosed as having a series of paradoxical inflammations during anti-TNF-α therapy. Since his
paradoxical inflammations were not severe and opportunistic infections were excluded, IFX was cautiously continued
for refractory Crohn’s disease. Nine months later, not only his intrathoracic lesions but also his cutaneous lesions had
spontaneously resolved.
Conclusion: Physicians caring for patients with anti-TNF-α therapy should know that, based on a careful exclusion of
infectious agents and thoughtful assessment of the patient’s possible risks and benefits, paradoxical inflammations can
be resolved without the cessation of anti-TNF-α therapy.
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Tumor necrosis factor-alpha (TNF-α) is known to be one
of the key cytokines for granuloma formation in both
sarcoidosis and inflammatory bowel diseases. Infliximab,
which is a humanized chimeric monoclonal antibody
against TNF-α, is indicated for refractory Crohn’s disease,
and several reports have described its effectiveness for
refractory sarcoidosis. As the use of anti-TNF-α therapy
has been increasing, various paradoxical inflammations
such as cutaneous vasculitis, drug induced lupus and
sarcoidosis have been reported in recent years [1]. We
describe a patient of refractory Crohn’s disease who devel-
oped sarcoidosis and cutaneous vasculitis simultaneously
during anti-TNF-α antibody, infliximab, therapy.
Case presentation
In September 2000, 23-year old Japanese male developed
melena, fever, arthralgia and erythema nodosum (Fig. 1a).
After close examination, he was diagnosed with Crohn’s
disease. Prednisolone (PSL) (40 mg/day) in combination
with mesalazine (3000 mg/day) was introduced at first,
and then PSL was subsequently tapered to the mainten-
ance dose (5 mg/day). These induction therapies succeeded
in achieving partial remission for almost one year. In June
2002, his gastrointestinal symptoms relapsed, but the in-
crease of PSL to 40 mg/day failed to achieve remission.
After infliximab (IFX) therapy (intravenous IFX 5 mg/kg
every 6 weeks) was introduced, his disease gradually be-
came well controlled. In February 2011, he had repeated
arthralgia almost every 6 weeks after intravenous IFX. In
the following April, IFX was increased to 10 mg/kg for
every 8 weeks under the diagnosis of a secondary failure of
IFX at the local clinic.
In October 2012, he complained of slight dry cough
and an itchy eruption on both lower limbs, and he was
referred to our hospital due to the appearance of bilat-
eral hilar lymphadenopathy on chest X-ray examination
(Fig. 1b). On admission, his vital signs were normal and
an erythema on both lower limbs was present (Fig. 1c).
Laboratory findings were almost within normal limits.
Serum calcium, angiotensin-converting enzyme (ACE)
and soluble interleukin 2 receptor (sIL-2R) levels were
not elevated, but the titer of antinuclear antibody (ANA)
was considerably elevated to ×1280. A purified derivative
skin test (PPD) was negative (3 mm × 3 mm). Mycobac-
terium tuberculosis (Mtb) infection was carefully ex-
cluded because the result of QuantiFERON-TB 3-G
(QFT3-G) was negative where Mtb antigen value was
0.11 IU/ml, nil value 0.12 IU/ml and mitogen (positive
control) value over 10 IU/ml, and both repeated sputum
cultures and polymerase chain reaction (PCR) of sputum
samples as well as that of biopsy material taken at bron-
choscopy were all negative for Mtb. Chest computed
tomogram (CT) revealed mediastinal and bilateral hilarlymphadenopathy, and fine reticulonodular shadows in
broncho-vascular bundles on the bilateral upper lung
fields (Fig. 1d, upper panel). Positron emission tomog-
raphy (FDG-PET) scan indicated abnormally increased
FDG uptakes in the mediastinal and bilateral hilar lymph
nodes (Fig. 1d, lower panel), suggesting the possibility of
sarcoidosis or malignant lymphoma. Broncho-alveolar
lavage fluid (BALF) showed an increase in the ratio of
lymphocyte counts (44 %), but the ratio of CD4/8 was
not elevated (1.1). The culture in BALF was negative for
any pathogens including Mtb. Trans-bronchial lung
biopsy (TBLB) showed several non-caseating epithelioid
cell granulomas including Langhans giant cells in the
interstitium of the peripheral alveolar legions (Fig. 2a).
These findings were compatible with sarcoidosis. Because
Propionibacterium acnes (P. acnes) is the only bacteria
that has been cultured from sarcoid-granuloma [2], we in-
vestigated immunohistochemical staining using anti P.
acnes antibody, but immunoreactivity was negative in the
TBLB specimens (Fig. 2b). The skin biopsy specimen of
the right limb was diagnosed as leukocytoclastic vasculitis
(Fig. 2c, d), which is the most common type of vasculitis
that occurs during anti-TNF-α therapy. Based on the sim-
ultaneous development of sarcoidosis and cutaneous vas-
culitis, the patient was diagnosed as having a series of
paradoxical inflammations during anti-TNF-α therapy.
Since opportunistic infections were carefully excluded, his
paradoxical inflammations were not severe and he wanted
to continue anti-TNF-α therapy for his refractory Crohn’s
disease, IFX (10 mg/kg for every 8 weeks) was continued
cautiously. Nine months later, not only his intrathoracic
lesions but also his cutaneous lesions had spontaneously
improved without any opportunistic infections in the
lungs while under IFX treatment (Fig. 1e).
Discussion
TNF-α is one of the key cytokines in the formation of
non-caseating epithelioid cell granulomas in both sarcoid-
osis [3, 4] and Crohn’s disease [5]. IFX, anti-TNF-α anti-
body, is widely used for refractory Crohn’s disease and
there is increasing evidence that it is effective for refrac-
tory sarcoidosis [6]. Recently, it has been reported that
anti-TNF-α therapy induces so-called paradoxical inflam-
mations, including anti-nuclear antibody production, drug
induced lupus, vasculitis and sarcoid-like granulomatous
disease [1, 7–10]. Although the mechanism responsible
for the development of sarcoidosis during anti-TNF-α
therapy is not well understood, the simultaneous develop-
ment of sarcoidosis and cutaneous vasculitis in the present
case may suggest an underlying pathogenesis for the para-
doxical inflammations. To the best of our knowledge, this
is the first case that simultaneously developed sarcoidosis
and cutaneous vasculitis during IFX therapy for refractory
Crohn’s disease.
Fig. 1 a A chart delineating the clinical course of this case. After infliximab was increased to 10 mg/kg for every 8 weeks, both sarcoidosis and
leukocytoclastic vasculitis developed. b A chest X ray on admission revealed bilateral hilar lymphadenopathy. c Scattered eruption on the right thigh on
admission. d A Chest CT scan on admission revealed bilateral hilar lymphadenopathy and fine reticulo-nodular shadows in the peri-bronchovascular
region of the bilateral upper lobes (upper panel) and positron emission tomography (FDG-PET) scan indicated increased FDG uptakes in the bilateral
hilar lymph nodes (lower panel). e Nine months later, the bilateral hilar lymphadenopathy and the upper lobe reticulo-nodular shadows had
spontaneously resolved
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In 2010, Ramos-Casals and colleagues reported that
there had been 38 cases of sarcoidosis or “sarcoid like”
granulomatous disease during anti-TNF-α therapy out of
1370 adult patients of systemic autoimmune diseases
under the use of biological agents [9, 10]. Etanercept
(ETN), a humanized TNF-α2 receptor, was used in 75 %
of the cases, but IFX was used in only 25 % of the cases.
Anti-TNF-α therapy was withheld in most of these cases
because of the possibility of respiratory infection or
severe symptoms of sarcoidosis, and in some cases
systemic corticosteroid and/or anti tuberculosis therapy
were tried. In only a few cases, as well as in our case,
anti-TNF therapy was continued carefully after oppor-
tunistic infections were excluded, because the original
diseases were severe and could not be controlled without
anti-TNF therapy. Both symptoms and abnormal findingscaused by sarcoidosis spontaneously resolved in those
cases. Since it can be difficult to determine whether anti-
TNF-α therapy should be continued or not, a course of
treatment must be based on a careful assessment of the
patient’s possible risks and benefits.
Differences between IFX and ETN in host immunity
There are some structural and pharmacological differ-
ences between ETN and IFX [11]. It is speculated that
because the effect of ETN is weaker and shorter in terms
of its TNF-α neutralization capacity than that of IFX,
reactivated TNF-α is viable and more likely to induce
paradoxical reactions. IFX is a chimeric monoclonal
antibody of mouse Fab and human IgG1 Fc. IFX binds
both monomer and trimer forms of soluble TNF-α and
form a stable complex. IFX also forms a stable complex
with transmembrane forms of TNF-α on the surface of
ca
db
Fig. 2 a Trans-bronchial lung biopsy (TBLB) revealed non-caseating epithelioid cell granuloma with Langhans giant cells, which were compatible
with sarcoidosis (HE staining, ×400). b Anti Propionibacterium acnes antibody staining was negative within this specimen. c Skin biopsy from the
right thigh shown in Fig. 1d revealed leukocytoclastic vasculitis in the superficial layer of the sub-dermal portion. (HE staining, ×100). d A high-power
field of Fig. 2c revealed remarkable infiltration of neutrophils around small capillaries and leukocytoclasis. (Elastica-Masson staining, ×400)
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body-dependent cell-mediated cytotoxity), CDC (com-
plement-dependent cytotoxity) and reverse signaling,
strongly inducing the apoptosis of inflammatory cells.
Thus, IFX is effective for the treatment of Crohn’s dis-
ease. On the other hand, IFX compromises the patient’s
immunity, resulting in the reactivation of intracellular
latent infection by P. acnes or Mtb. P. acnes is the only
bacteria that has been cultured from sarcoid-granuloma
[2], and Mtb catalase-peroxidase (mKatG) was reported
to be a pathogenic antigen in sarcoidosis [12]. Although
the P.acnes antibody staining was negative in our TBLB
specimen, this may not exclude the possibility of reacti-
vation of intracellular latent infection, because a TBLB
specimen is too small for P.acnes antibody staining and
it is difficult to detect the dormant phase of P. acnes. It
is important to closely investigate the possibility of above
mentioned microorganisms to determine whether anti-
TNF-α therapy should be continued or not.
Possible mechanisms of simultaneous development of
both sarcoidosis and leukocytoclastic vasculitis as
paradoxical inflammations during anti-TNF-α therapy
It is known that some patients develop a so-called
secondary failure, in which a symptom of the original
disease relapses and infusion reaction may appear in the
course of IFX treatment. A neutralizing auto-antibody
against IFX (anti-IFX Ab) may be deeply related to the
pathogenesis of this secondary failure [13]. According toa previous report [14], the speculated mechanisms of
anti-IFX Ab production are as follows. First, IFX induces
apoptosis in pathogenic macrophages, resulting in a
reduction of TNF-α production and granuloma forma-
tion in the intestinal submucosa. Next, inadequately acti-
vated T lymphocytes recognize the apoptotic debris
including auto-antigens. Then, the further activated Th1
and Th2 system induces production of auto-antibodies
such as ANA, anti-double strand DNA (dsDNA) anti-
body and also anti-IFX Ab [1]. Because IFX is a
mouse/human chimeric anti TNF-α antibody, IFX is
more likely to trigger anti-IFX Ab production than
ETN, a synthesized anti TNF-α receptor [13]. It has
also been reported that the appearance of anti-IFX Ab
is closely related to the occurrence of ANA or anti-
DNA-antibody [15]. Finally, anti-IFX Ab and ANA
production is likely to cause sarcoid-like granuloma-
tous disease and leukocytoclastic vasculitis, respect-
ively. To date, 113 cases of vasculitis during anti-TNF
therapies have been reported [16]. The most common
clinical manifestation is cutaneous vasculitis, which is
pathologically compatible with leukocytoclastic vascu-
litis. It has been suggested that when immune complex
formations such as TNFα/anti-TNFα Ab or autoantigen/
ANA are deposited in small capillaries, complement
cascades are activated and type III hypersensitivity reac-
tion may occur. Additionally, immune dysregulation or a
cytokine imbalance may underlie the development of
vasculitis in patients during anti-TNF therapies.
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In a review addressing thoracic manifestations of inflam-
matory bowel disease [17], it was reported that there have
been 53 cases of inflammatory bowel disease coexisting
with sarcoidosis; underlying ties between the two entities
were also suggested. Later in 2012, Colin et al. mentioned
that, based on recent genome wide analyses, a susceptibil-
ity locus for sarcoidosis is shared by Crohn’s disease [18]. It
is also difficult in clinical settings to differentiate whether
the appearance of sarcoid-like granulomas during anti-
TNF-α therapy be true paradoxical inflammations or intra-
thoracic manifestation of Crohn’s disease or co-existence
of Crohn’s disease and sarcoidosis.
Conclusion
In summary, we report a very rare case of the simultaneous
development of sarcoidosis and cutaneous vasculitis in a
patient with refractory Crohn’s disease during IFX therapy
and both of which resolved spontaneously without the ces-
sation of IFX. Physicians caring for patients with anti-TNF-
α therapy should determine whether anti-TNF-α therapy
be continued or not, based on a careful exclusion of infec-
tious agents and thoughtful assessment of the patient’s pos-
sible risks and benefits.
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